Search Results

Stalicla SA announces the successful completion of the first closing of its Series B financing round, securing $17.4 million.

Rapport Therapeutics, Inc. (Nasdaq: RAPP) today announced the closing of its initial public offering of 9,200,000 shares of its common stock at a public offering price of $17.00 per share, which includes 1,200,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering.

Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global, clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced it successfully completed its first-in-human Phase 1 study of CBP-174 designed to evaluate safety, tolerability, and pharmacokinetics (PK) in healthy adults.

The global healthcare CRM market is projected to register growth at a CAGR of 14.6% during the forecast period of 2018 to 2023 and gain a valuation of US$ 17.4 Bn by 2023.

Aphios Corporation announced today that it has been granted US Patent No. 11,981,174 for CCR5 and CD4 siRNA-targeted therapeutics for treatment of HIV-1 and other diseases.

Greenwich LifeSciences, Inc. announced that it has entered into a securities purchase agreement with its Chief Executive Officer, Snehal Patel, for the purchase and sale of 174,825 shares of its common stock at a purchase price of $14.30 per share in a private placement.

According to Emergen Research, the global intelligent drug discovery market size was USD 360.90 million in 2020 and is expected to reach USD 5,174.24 million in 2028 and register a revenue CAGR of 39.4% during the forecast period, 2021-2028.

Ventyx Biosciences, Inc. announced today that it has entered into a stock purchase agreement for the sale of 11,174,000 shares of its common stock at an offering price of $8.95 per share.

Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for patent application number 3,174,137 titled, “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors.”